Download Sample
Add to CartTotal Artificial Heart Market
By Therapy;
Bridge To Transplant, Destination Therapy, Bridge To Decision, and OthersBy Power Source;
Internal Battery and External BatteryBy Product Type;
Syncardia Systems, Bivacor Rotary Total Artificial Heart, Carmat, and OthersBy Application;
Dilated Cardiomyopathy, Ischemic Cardiomyopathy, and OthersBy End User;
Hospitals, Specialty Centers, and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Total Artificial Heart Market Overview
Total Artificial Heart Market (USD Million)
Total Artificial Heart Market was valued at USD 111.94 million in the year 2024. The size of this market is expected to increase to USD 367.74 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 18.5%.
Total Artificial Heart Market
*Market size in USD million
CAGR 18.5 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 18.5 % |
| Market Size (2024) | USD 111.94 Million |
| Market Size (2031) | USD 367.74 Million |
| Market Concentration | Low |
| Report Pages | 339 |
Major Players
- SynCardia Systems, LLC
- Abbott Laboratories
- Carmat
- BiVACOR Inc.
- Cleveland Heart, Inc.
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Total Artificial Heart Market
Fragmented - Highly competitive market without dominant players
The Total Artificial Heart Market is accelerating as cardiothoracic centers and transplant programs increasingly adopt fully implantable biventricular circulatory systems for patients with end-stage heart failure. Nearly 65% of advanced cardiac units now offer total artificial hearts as bridge-to-transplant or destination therapy options. This adoption trend is fueling dynamic innovation and market expansion, facilitated by collaboration between cardiac surgeons and bioengineering teams focused on improving hemodynamic performance.
Next-Gen Designs Improve Mobility & Monitoring
Approximately 62% of device manufacturers are developing next-generation models with miniaturized pumps, pulsatile-flow technology, wireless power delivery, and integrated sensor platforms for real-time performance monitoring. These technological advancements enhance patient mobility, reduce infection risks, and support long-term implant stability. Synergic R&D among clinicians and system engineers is driving patient-centered design evolution.
Protocol Standardization Enhances Safety
Clinical trials and post-market surveillance programs spearheaded by hospitals, research consortia, and device companies have resulted in a 59% increase in adoption of standardized implantation protocols. These cross-functional collaborations support shared registries, surgical training, and data-driven patient monitoring—promoting growth through procedural consistency and safety.
Smart, Adaptive Support Systems on the Horizon
Looking ahead, more than 70% of next-wave devices are expected to feature adaptive physiologic control algorithms, remote telemetry capabilities, and biocompatible surface coatings to reduce thrombosis. These innovations herald a move toward intelligent circulatory support ecosystems, enabling personalized cardiac support and long-term quality of life enhancement for patients awaiting transplant or seeking permanent assistance.
Total Artificial Heart Market Recent Developments
-
In April 2023, BiVACOR Inc. unveiled its next-generation total artificial heart, incorporating cutting-edge magnetic levitation technology that enhances durability and minimizes wear and tear. This new model offers improved hemodynamic performance and biocompatibility, with the goal of achieving better patient outcomes and extending the device's lifespan. This launch represents a pivotal advancement in artificial heart technology, solidifying BiVACOR's position as a leader in the market.
-
In May 2023, SynCardia Systems LLC merged with a prominent cardiac device manufacturer to strengthen its market presence and technological capabilities. This merger seeks to leverage the strengths of both companies in the research, development, and distribution of total artificial hearts. The strategic alliance is anticipated to boost innovation, enhance production efficiencies, and broaden global market reach, ultimately improving the availability and affordability of artificial heart solutions.
Total Artificial Heart Market Segment Analysis
In this report, the Total Artificial Heart Market has been segmented by Therapy, Power Source, Product Type, Application, End User, and Geography.
Total Artificial Heart Market, Segmentation by Therapy
The Total Artificial Heart Market has been segmented by Therapy into Bridge To Transplant, Destination Therapy, Bridge To Decision, and Others.
Bridge To Transplant
Bridge to transplant therapy dominates the total artificial heart market due to its critical role in sustaining patients awaiting heart transplantation. These devices help maintain cardiac output and systemic perfusion during the wait time. Growing cases of advanced heart failure and organ shortages are boosting reliance on this strategy. The improved survival rates linked to this therapy are driving segment growth.
Destination Therapy
Destination therapy is intended for patients ineligible for heart transplantation, providing a permanent solution for end-stage heart failure. The therapy’s appeal lies in enhanced quality of life and survival without transplantation. Technological advancements are making devices smaller and more efficient, expanding their applicability. Regulatory support is aiding reimbursement frameworks for this long-term treatment option.
Bridge To Decision
Bridge to decision therapy is used to stabilize critically ill patients while determining the most suitable long-term treatment path. It serves as an important interim life-saving intervention. This segment is witnessing growth due to increased recognition of its value in emergency settings. Healthcare systems are integrating it within broader heart failure management protocols.
Others
This category includes compassionate-use cases, investigational therapies, or niche clinical trials. While smaller in scale, these applications contribute to research and innovation in artificial heart systems. The segment supports clinical evaluation of new designs and technologies. Adoption is growing as experimental therapies gain regulatory pathways.
Total Artificial Heart Market, Segmentation by Power Source
The Total Artificial Heart Market has been segmented by Power Source into Internal Battery and External Battery.
Internal Battery
Internal batteries offer greater mobility and patient independence by eliminating the need for external power connections. This power source supports a higher quality of life and improved device wearability. Innovations in lithium-ion and biocompatible power cells are enhancing performance and lifespan. The trend toward fully implantable systems is boosting demand in this segment.
External Battery
External batteries remain essential for total artificial heart systems due to their longer power supply capabilities. They are widely used in hospital settings or during initial recovery stages. These batteries allow easy monitoring and replacement. Despite being less mobile, they ensure continuous device reliability, especially in critical cases.
Total Artificial Heart Market, Segmentation by Product Type
The Total Artificial Heart Market has been segmented by Product Type into SynCardia Systems, Bivacor Rotary Total Artificial Heart, Carmat, and Others.
SynCardia Systems
SynCardia dominates the total artificial heart market, particularly with its clinically proven 70cc and 50cc TAH devices. The company's FDA and CE approvals have driven its use globally. Its pneumatically driven technology is well-established in transplant bridging applications. The availability of portable drivers has improved patient mobility.
Bivacor Rotary Total Artificial Heart
Bivacor offers a next-generation rotary total artificial heart, designed for durability and compactness. It uses a centrifugal pump system that allows a single moving part to reduce wear and failure risk. Its magnetic levitation technology is setting new benchmarks for mechanical performance. The product is in advanced clinical trials and attracting global investment.
Carmat
Carmat’s bioprosthetic artificial heart is designed to replicate the natural cardiac cycle with biomimetic materials. It uses sensors and microprocessors for real-time blood flow adaptation. The device has gained conditional CE marking and is being used in select European centers. Carmat focuses on long-term destination therapy for advanced heart failure patients.
Others
This segment includes emerging manufacturers and research institutions developing novel heart replacement technologies. These innovations include fully implantable soft robotics and AI-controlled pumps. Though not yet commercialized, such developments hold future promise. Government-funded studies and academic collaborations are driving activity here.
Total Artificial Heart Market, Segmentation by Application
The Total Artificial Heart Market has been segmented by Application into Dilated Cardiomyopathy, Ischemic Cardiomyopathy, and Others.
Dilated Cardiomyopathy
Dilated cardiomyopathy is the leading application, as patients with this condition often progress to end-stage heart failure. Artificial hearts provide life-saving support when medical therapy fails. Increasing prevalence and earlier diagnosis are expanding the pool of eligible candidates. Improved survival outcomes are driving clinical acceptance of artificial hearts.
Ischemic Cardiomyopathy
Ischemic cardiomyopathy results from reduced blood flow due to coronary artery disease, leading to weakened heart muscles. Total artificial hearts offer an option for patients unresponsive to revascularization or medication. Advancements in device miniaturization and biocompatibility make this a growing segment. Patient awareness and clinical success are enhancing market uptake.
Others
This category includes congenital heart defects, myocarditis, and post-chemotherapy cardiac failure. Though smaller in volume, these cases require customized artificial heart solutions. Ongoing innovation and compassionate-use programs are expanding accessibility. Specialized cardiac centers are increasingly catering to such high-risk populations.
Total Artificial Heart Market, Segmentation by End User
The Total Artificial Heart Market has been segmented by End User into Hospitals, Specialty Centers, and Others.
Hospitals
Hospitals are the primary end users due to their capability to conduct high-risk cardiac surgeries. These facilities offer multi-disciplinary care teams and access to emergency infrastructure. Artificial heart implantation is mostly carried out in tertiary care and transplant centers. Hospitals also serve as hubs for training and device trials.
Specialty Centers
Specialty centers focus exclusively on advanced heart failure and transplant management. These centers are growing in number as more institutions develop dedicated cardiac units. Their expertise allows for patient selection, device management, and long-term monitoring. Specialty centers are key partners for device developers in real-world evidence generation.
Others
This segment includes military hospitals, research institutions, and mobile transplant units. Their use of total artificial hearts is often for experimental or emergency cases. These centers support testing of emerging technologies and protocols. Collaborations between public and private entities are fostering growth here.
Total Artificial Heart Market, Segmentation by Geography
In this report, the Total Artificial Heart Market has been segmented by Geography into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
Regions and Countries Analyzed in this Report
Total Artificial Heart Market Share (%), by Geographical Region
North America
North America leads with a market share of approximately 38.6%, backed by FDA-approved devices and advanced transplant centers. The U.S. sees high adoption of artificial hearts for bridge-to-transplant therapies. Favorable reimbursement policies and strong clinical infrastructure drive regional dominance. Continuous innovation and funding keep growth sustained.
Europe
Europe holds about 28.1% of the market, with strong contributions from France, Germany, and the UK. CE-marked devices like Carmat have gained traction in select hospitals. Government support and public-private R&D initiatives enhance adoption. The region’s aging population fuels demand for advanced cardiac support.
Asia Pacific
Asia Pacific accounts for nearly 18.9% market share, driven by healthcare modernization in China, Japan, and India. Medical tourism and increasing heart failure prevalence contribute to rising adoption. Local production of devices and surgeon training programs are expanding access. The region shows high potential for clinical trial expansion.
Middle East & Africa
This region comprises about 8.2% of the market, led by countries like the UAE, Saudi Arabia, and South Africa. High investment in healthcare infrastructure is supporting access to advanced cardiac therapies. However, limited transplant programs in rural areas constrain full-scale adoption. International partnerships are helping bridge gaps.
Latin America
Latin America holds a 6.2% share, with Brazil and Mexico driving regional demand. Emerging transplant programs and growing awareness about heart failure treatment support growth. The market is limited by cost barriers and low device availability. Nonetheless, pilot projects and academic partnerships are opening up new opportunities.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Total Artificial Heart Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Technological Advancements
- Growing Incidence of Heart Failure
- Increasing Demand for Organ Transplants
- Aging Population
-
Rising Healthcare Expenditure- The rising healthcare expenditure globally is a significant driver of growth in the total artificial heart market. As healthcare budgets expand, there is a greater capacity for healthcare systems to invest in advanced medical technologies and procedures, including total artificial heart implants. The increasing allocation of funds towards cardiac care, particularly for patients with end-stage heart failure, enables healthcare providers to offer total artificial heart therapy as a viable treatment option, thereby driving market growth.
The rising healthcare expenditure facilitates improvements in healthcare infrastructure, workforce training, and patient access to specialized cardiac care facilities. These investments create an enabling environment for the adoption and utilization of total artificial heart systems, as they enhance the availability of advanced surgical facilities, perioperative support services, and postoperative rehabilitation programs. Additionally, the growing emphasis on value-based care and patient-centered approaches in healthcare delivery encourages healthcare systems to invest in innovative therapies such as total artificial hearts, which offer the potential to improve patient outcomes and quality of life while optimizing healthcare resource utilization. Overall, the rising healthcare expenditure is expected to continue fueling growth in the global total artificial heart market, driving advancements in cardiovascular medicine and expanding access to life-saving treatments for patients with end-stage heart failure.
Restraints
- High Cost of Treatment
- Limited Availability of Donor Hearts
- Surgical Complexity
- Risk of Complications
-
Regulatory Hurdles- Regulatory hurdles pose significant challenges to the global total artificial heart market, influencing the development, approval, and commercialization of total artificial heart systems. The stringent regulatory requirements imposed by regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), necessitate extensive preclinical and clinical testing to demonstrate the safety, efficacy, and quality of total artificial heart devices. Manufacturers must navigate complex regulatory pathways, including premarket approval (PMA) or CE marking processes, which require comprehensive data submissions and adherence to rigorous regulatory standards.
Variations in regulatory frameworks across different geographical regions add complexity to the commercialization of total artificial heart systems, leading to delays in market entry and increased compliance costs for manufacturers. Differences in regulatory requirements, approval timelines, and post-market surveillance obligations necessitate strategic planning and regulatory expertise to navigate the regulatory landscape effectively. Moreover, evolving regulatory guidelines and the introduction of new regulations, such as the Medical Device Regulation (MDR) in the European Union, further contribute to regulatory uncertainty and compliance challenges for manufacturers in the global total artificial heart market. As a result, regulatory hurdles remain a critical consideration for stakeholders, shaping product development strategies, market entry decisions, and overall competitiveness in the total artificial heart market.
Opportunities
- Market Expansion in Emerging Economies
- Development of Miniaturized Devices
- Advancements in Biocompatible Materials
- Enhanced Patient Monitoring Solutions
-
Collaborative Research Initiatives- Collaborative research initiatives play a pivotal role in driving innovation and advancing the field of total artificial heart technology. In the global total artificial heart market, collaboration among academic institutions, healthcare providers, industry stakeholders, and regulatory agencies fosters knowledge exchange, interdisciplinary expertise, and shared resources to address complex scientific challenges. By pooling together diverse perspectives and complementary skill sets, collaborative research initiatives accelerate the development and validation of novel total artificial heart systems, facilitating the translation of scientific discoveries into clinical applications.
Collaborative research initiatives enable stakeholders to leverage collective resources and infrastructure, such as preclinical testing facilities, clinical trial networks, and data repositories, to conduct robust scientific investigations and clinical studies. These collaborative efforts facilitate the generation of high-quality evidence regarding the safety, efficacy, and performance of total artificial heart devices, supporting regulatory submissions and market approval processes. Additionally, collaborative research fosters a culture of innovation, encourages open communication, and promotes transparency within the total artificial heart community, ultimately driving advancements in patient care and outcomes. Overall, collaborative research initiatives are instrumental in shaping the future of the global total artificial heart market, fostering a collaborative ecosystem that accelerates scientific progress and improves the lives of patients with end-stage heart failure.
Competitive Landscape Analysis
Key players in Global Total Artificial Heart Market include,
- SynCardia Systems, LLC
- Abbott Laboratories
- Carmat
- BiVACOR Inc.
- Cleveland Heart, Inc.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Therapy
- Market Snapshot, By Power Source
- Market Snapshot, By Product Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Total Artificial Heart Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Technological Advancements
- Growing Incidence of Heart Failure
- Increasing Demand for Organ Transplants
- Aging Population
- Rising Healthcare Expenditure
- Restraints
- High Cost of Treatment
- Limited Availability of Donor Hearts
- Surgical Complexity
- Risk of Complications
- Regulatory Hurdles
- Opportunities
- Market Expansion in Emerging Economies
- Development of Miniaturized Devices
- Advancements in Biocompatible Materials
- Enhanced Patient Monitoring Solutions
- Collaborative Research Initiatives
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Total Artificial Heart Market, By Therapy, 2021 - 2031 (USD Million)
- Bridge To Transplant
- Destination Therapy
- Bridge To Decision
- Others
- Total Artificial Heart Market, By Power Source, 2021 - 2031 (USD Million)
- Internal Battery
- External Battery
- Total Artificial Heart Market, By Product Type, 2021 - 2031 (USD Million)
- Syncardia Systems
- Bivacor Rotary Total Artificial Heart
- Carmat
- Others
- Total Artificial Heart Market, By Application, 2021 - 2031 (USD Million)
- Dilated Cardiomyopathy
- Ischemic Cardiomyopathy
- Others
- Total Artificial Heart Market, By End User, 2021 - 2031 (USD Million)
- Hospitals
- Specialty Centers
- Others
- Total Artificial Heart Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Total Artificial Heart Market, By Therapy, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- SynCardia Systems LLC
- Abbott Laboratories
- Carmat
- BiVACOR Inc
- Cleveland Heart Inc
- Company Profiles
- Analyst Views
- Future Outlook of the Market